key: cord-0727689-58neee63
authors: Singh, Urvashi B.; Rophina, Mercy; Chaudhry, Rama; Senthivel, Vigneshwar; Bala, Kiran; Bhoyar, Rahul C.; Jolly, Bani; Jamshed, Nayer; Imran, Mohamed; Gupta, Ritu; Aggarwal, Praveen; Divakar, Mohit K.; Sinha, Subrata; Arvinden, V. R.; Bajaj, Anjali; Shamnath, Afra; Jain, Abhinav; Scaria, Vinod; Sivasubbu, Sridhar; Guleria, Randeep
title: Variants of concern responsible for SARS‐CoV‐2 vaccine breakthrough infections from India
date: 2021-11-25
journal: J Med Virol
DOI: 10.1002/jmv.27461
sha: 014a7311666bc2cbf7fca8a6ce07938366f07cc0
doc_id: 727689
cord_uid: 58neee63

Emerging reports of SARS‐CoV‐2 breakthrough infections entail methodical genomic surveillance for determining the efficacy of vaccines. This study elaborates genomic analysis of isolates from breakthrough infections following vaccination with AZD1222/Covishield and BBV152/Covaxin. Variants of concern B.1.617.2 and B.1.1.7 responsible for cases surge in April–May 2021 in Delhi, were the predominant lineages among breakthrough infections.

Vaccines have been one of the most powerful weapons against infectious diseases. The emergence of COVID-19 as a global pandemic has seen accelerated development as well as regulatory approvals for a variety of vaccines across the world. Immunity acquired from natural COVID-19 infection or vaccines is not absolute and reinfections postnatural COVID-19 infections, as well as vaccine breakthrough infections, are not uncommon. [1] [2] [3] The recent evidence from the United States suggests vaccine breakthrough infections to be approximately 0.01% in fully vaccinated populations. 4 One of the initial surveillance reports from a chronic care medical facility in India reported out of a total of 113 employees, 19 experienced vaccine breakthrough infections. 5 Genomic surveillance of vaccine breakthrough infections can provide useful insights into the genetic variants of SARS-CoV-2 that caused the infection. 2 Figure 1A . The patients had a mean age of 37 (21-92), of which 41 were males and 22 were females. None of the patients had any comorbidities which could act as a predisposing factor for breakthrough infections.

The mean depth of coverage of the genome sequences for the 63 viral isolates was 3953X (108.7X-17,435.5X) and it correlated with the viral load as reflected by the C t values. The patient details and genomic data are summarised in Table S1 . A phylogenetic tree was constructed following a previously published protocol 6 primarily been attributed to variants of concern and the proportion was similar to the prevalence throughout the United States, again during a period of high transmission. 4 While a number of vaccine breakthrough infections have been reported previously, it has been largely associated with nonsevere symptoms. Mortality due to COVID-19 was ascribed to 2% cases (primarily older population, average age = 82 years). 4 Of the 63 cases of vaccine breakthrough infections in the current study, including 36 who received full doses, there are no reports of mortality even though almost all cases presented with high-grade unremitting fever for 5-7 days. While total antibody levels for a subset of patients were high, they became infected nevertheless and presented to the emergency just like other patients, putting in doubt the protection offered and or clinical relevance of total IgG as a surrogate of COVID-19 immunity.

The present report is unique in many aspects. This is one of the first reports of symptomatic vaccine breakthrough infections, and breakthrough infections in a tertiary care setting apart from being the earliest reports of breakthrough infections with BBV152/Covaxin and B.1.617.2 variant of SARS-CoV-2. This report brings forth the role of highly transmissible variants of concern in causing breakthrough infections in the vaccinated population. 3, 8 We hope this early report of genomic analysis of breakthrough infections could provide guidance to further systematic cohort analysis on the efficacy of vaccines with respect to genetic variants of SARS-CoV-2.

SARS-CoV-2 reinfection: development of an epidemiological definition from India

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala

Vaccine breakthrough infections with SARS-CoV-2 variants

COVID-19 vaccine breakthrough infections reported to CDC-United States

Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility

Computational analysis and phylogenetic clustering of SARS-CoV-2 genomes

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Genetic epidemiology of variants associated with immune escape from global SARS-CoV-2 genomes

Coronavirus in India: Latest Map and Case Count

Global initiative on sharing all influenza data -from vision to reality

Computational protocol for assembly and analysis of SARS-nCoV-2 genomes. rr2020;4. Accessed

High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq nextgeneration sequencing

Variants of Concern responsible for SARS-CoV-2 vaccine breakthrough infections from India

The authors declare that there are no conflict of interests. 

The sequence data is available in GISAID (https://www.gisaid.org) with IDs EPI_ISL_2426235-EPI_ISL_2426245.

http://orcid.org/0000-0002-7381-1504Mohit K. Divakar http://orcid.org/0000-0002-6731-9249Vinod Scaria http://orcid.org/0000-0001-7644-7181